|
Amarin selloff creates attractive entry point, says Citi Citi analyst Joel Beatty believes the selloff yesterday in shares of Amarin (AMRN) brings an attractive entry point. He raised his price target for the stock to $23 from $20 and keeps a Buy rating on the name. The analyst sees five potential upside catalysts this year, including a likely supportive ICER cost-effectiveness review and potential priority review from the FDA. Further, while an acquisition of Amarin is possible, the company acquiring The Medicines Co. (MDCO) or Esperion (ESPR) "could also be a viable path," says Beatty. Read more at: https://thefly.com/landingPageNews.php?id=2901824 |
|
| aus der Diskussion: | Amarin - The Science Of Lipid Therapy |
| Autor (Datum des Eintrages): | Magnetfeldfredy (02.05.19 13:42:25) |
| Beitrag: | 506 von 1,840 (ID:60471218) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |